The fate of Alcon Inc. has long been under consideration by parent company Novartis AG. In early 2018, the Basel, Switzerland-based company said it expected to conduct a spin-off or IPO for its ophthalmic devices business. Now, it has started to detail those plans, committing to a spin-off of the Alcon devices business that's slated to complete during the first half of next year.